December 22, 2008

Evolva submits CTA for first-in-man study with new cardiovascular drug

Evolva SA, an international biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, today announced the filing of a Clinical Trial Application (CTA) for EV-077-3201-2TBS. This is a new chemical entity that is being developed for reduction of cardiovascular morbidity and mortality in patients who are hypo-responders or resistant to Aspirin and/or Clopidogrel. It is also being developed for treatment of proteinuric kidney diseases.
PDF Download

read more »

December 15, 2008

ENTREMED Focuses on development of ENMD-2076

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company announced today plans to focus the Company’s resources on its most promising near-term product candidate, ENMD-2076, an Aurora/angiogenesis kinase inhibitor, as part of the Company’s overall plan to lower operating costs and preserve capital. The plan calls for acceleration of the Company’s 2009 clinical objectives for ENMD-2076, effectively transitioning the Company into a clinicallyfocused operation.
PDF Download

read more »

December 11, 2008

Aravis in Banco Magazine Nr 43 Winter 2008 German and French versions

Wie das “BANCO Sustainability Fundranking 2008” zeigt (siehe www.banco.ch, Leitartikel), vermag nur eine Minderheit der in der Schweiz zugelassenen SRI-Fonds gehobenen Nachhaltigkeits-Kriterien zu genügen: Nicht genug damit, dass vielfach das Who is who fossiler Energiekonzerne in den Portfolios zu finden ist; nein, viele
Positionen sind von Unternehmen besetzt, die zwar auf den ersten Blick in nachhaltigen Bereichen tätig sind, sich aber bei genauerem Hinsehen oft als “vorbestraft”
entpuppen, weil sie gegen Umweltgesetze oder Arbeitsrechte verstossen haben.
PDF Dowload German version
PDF Download French version

read more »

December 08, 2008

Affymetrix Completes Acquisition of Panomics

Affymetrix, Inc. (Nasdaq: AFFX) today announced the completion of its acquisition of Panomics, Inc., a privately held, Fremont, Calif.-based company which offers a powerful suite of assay products for a wide variety of low- to mid-plex genetic, protein, and cellular analysis applications.
PDF Download

read more »

November 13, 2008

Ambrx Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated

Ambrx Inc. today announced Phase I/II clinical trial data demonstrating that ARX201, the company’s long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I (IGF-I) levels while delivering an acceptable safety and tolerability profile in adults with Growth Hormone deficiency. The results of this trial support further evaluation of ARX201 as an option for the treatment of adult growth hormone deficiency (AGHD).
PDF Download

read more »

November 12, 2008

EntreMed Reports Clinical Program Progress and Company Update

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clinical program updates for the third quarter 2008 and remaining fourth quarter 2008 objectives. The updates were given during a podium presentation by EntreMed President & CEO, James S. Burns, and web cast at the Rodman & Renshaw 10th Annual Healthcare Conference, being held this week in New York. An archive of Mr. Burns’ live presentation is available on the Company’s web site at www.entremed.com and can be accessed for 60 days.
PDF Download

read more »

November 11, 2008

Affymetrix to Acquire Panomics

Affymetrix Inc. (Nasdaq: AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, Calif.-based company that offers a powerful suite of assay products for a wide variety of low to mid-plex genetic, protein and cellular analysis applications. The acquisition will strengthen Affymetrix’ position in high-growth validation and routine-testing market segments. The combination will also enable a more complete customer workflow, beginning with whole-genome Affymetrix microarray studies and then focusing on genes and proteins of interest with the Panomics products.
PDF Download

read more »

November 10, 2008

Evolva receives funding from the Global Cardiovascular Innovation Center

Evolva today announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). The funding is to advance the development of Evolva’s EV-077 compound series for cardiovascular disease and to explore the formation of a dedicated cardiovascular clinical unit to be based in Cleveland, Ohio.
PDF Download

read more »

November 10, 2008

EntreMed’s MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta(R)) in non-small cell lung cancer patients.
PDF Download

read more »

November 07, 2008

Telormedix Raises 21 Mio CHF in Series A Financing

Telormedix SA, a leader in novel immunotherapeutic molecules , has announced the closing of its first Series A equity investment round raising 21 Mio CHF (€13.1 million, $19 million), one of the largest Series A round in Switzerland for a biotech company in 2008. The round was supported by an international syndicate of investors, led by Aravis Venture (Basel, Switzerland), a leading Swiss venture capital firm. Proquest Investments (Princeton-San Diego, USA), a first tier US venture capital co-invested in their first investment in Europe. The round was further supported by a syndicate of investors, including BSI S.A. (Lugano, Switzerland), Nextech Venture (Zurich Switzerland) and Generali Insurance Group (Italy).
PDF Downlaod

read more »

November 03, 2008

Synosia Therapeutics Starts Phase IIa Trial of Nepicastat for Treatment of Post-Traumatic Stress Disorder (PTSD)

Synosia Therapeutics today announced the start of a phase IIa clinical trial with nepicastat (SYN-117), for the treatment of post-traumatic stress disorder (PTSD).
PDF Download

read more »

October 30, 2008

Aravis in Suisse Eole Newsletter

Aravis ist seit 2001 in der Risikokapital-Finanzierung von nicht-börsenkotierten Unternehmen tätig. Der Fokus der Finanzierungen liegt bei jungen und innovativen Wachstumsunternehmen in den Bereichen Biotechnologie und erneuerbare Energien. Das Management-Team von Aravis ist seit 1994 in der Risikokapital-
Finanzierung tätig und hat bis heute weltweit über 90 private Unternehmen vor allem in Europa und den USA finanziert.
PDF Download

read more »

October 22, 2008

S*Bio's Novel Anti-Cancer Drug SB939 demonstrates superior profile

S*BIO Pte Ltd today announced that multiple presentations of pre-clinical and early clinical data for its HDAC inhibitor SB939 will be made at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” in Geneva, Switzerland. The results demonstrate that the “best-in-class” pre-clinical profile of S*BIO’s novel anti-cancer drug SB939 translates into the clinic.
PDF Download

read more »

September 18, 2008

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the United States. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.
PDF Download

read more »

July 28, 2008

IKARIA® Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants

Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inhaled carbon monoxide for use in the reduction of the incidence and severity of delayed graft function (DGF) in patients undergoing solid organ transplantation.
PDF Download

read more »

July 22, 2008

Private-Equity-Anlagen in erneuerbare Energien mit Schweizer Rechtsstruktur

Das neue Kollektivanlagengesetz (KAG) ermöglicht Investoren mittels Swiss Limited Partnerships endlich den direkten Zugang zu Schweizer Private-Equity-«Funds». Somit können Investoren ihre Anlagen mit Risikokapitalinvestitionen – welche unter der Aufsicht der Eidgenössischen Bankenkommission (EBK) stehen –  diversifizieren. Diese Investitionen korrelieren nicht mit den öffentlichen Finanzmärkten. Die erste Swiss Limited Partnership, welche von der EBK bewilligt wurde, investiert in erneuerbare Energien. Nachfolgend die ersten praktischen Erfahrungen.
PDF Download

read more »

July 21, 2008

IKARIA’S INOFLO (NITRIC OXIDE) FOR INHALATION APPROVED IN JAPAN

Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved INOflo® (nitric oxide) for inhalation for improvement of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. INOflo (brand name INOmax® in the United States) has been shown to improve oxygenation and reduce the need for ECMO, a highly invasive cardiopulmonary bypass procedure.
PDF Download

read more »

June 24, 2008

IKARIA INTRODUCES DR. MICHAEL COOREMAN AS VICE PRESIDENT OF TRANSLATIONAL MEDICINE

Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced that Michael Cooreman, M.D., has been introduced as Vice President of
Translational Medicine, reporting to Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria.
PDF Download

read more »

May 19, 2008

IKARIA COMPLETES DOSING OF PHASE 1A CLINICAL STUDY FOR IK-1001 (SODIUM SULFIDE) FOR INJECTION

Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that it has completed dosing of its Phase 1a trial for its drug candidate, IK-1001 (sodium sulfide) for injection.
PDF Download

read more »

May 09, 2008

Evolva Subsidiary Signs $22.8 Million Antibacterial Contract with US Army Research Office, Builds Out US Operations

Genetic Chemistry Inc. (Palo Alto, USA), a subsidiary of Evolva SA (Basel, Switzerland) announced today that it has signed a contract with the US Army Research Office (ARO), working in conjunction with the Defense Threat Reduction Agency (DTRA), to discover novel therapeutics against the gram negative bacterial pathogen Burkholderia pseudomallei (a CDC category B bioterrorism agent that causes the disease melioidosis). Over the contract period funding could amount to $22.8 million.
PDF Download

read more »

January 09, 2008

Omeros Corporation Files Registration Statement for Proposed Initial Public Offering

Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co-lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.
PDF Download

read more »

January 09, 2008

IKARIA APPOINTS DANIEL TASSÉ AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Daniel Tassé has been appointed President and Chief Executive Officer. Mr. Tassé succeeds David Shaw, who has served as Chairman and interim CEO since the creation of Ikaria Holdings in March 2007 and will now serve as Executive Chairman and Chairman of the Board.
PDF Download

read more »